Drug Trial News

RSS

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

ARIAD Pharmaceuticals, Inc. today announced initial clinical findings on ponatinib in patients with advanced acute myeloid leukemia (AML).

3 Jun 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

3 Jun 2011

APC8015F investigational vaccine improves survival of prostate cancer patients

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4.

3 Jun 2011

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease.

3 Jun 2011

Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis

Teva Pharmaceutical Industries Ltd. today announced completion of patient enrollment for the GALA (Glatiramer Acetate Low-frequency Administration) trial.

3 Jun 2011

Angiotensin receptor blockers do not increase risk of cancer: FDA

The U.S. Food and Drug Administration today announced that a group of medications used to control high blood pressure, called angiotensin receptor blockers (ARBs), do not increase the risk of developing cancer in patients using the medications.

3 Jun 2011

Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

iBio, Inc. today announced positive interim results from a Phase 1 clinical trial of an iBioLaunch platform-produced subunit vaccine directed against Influenza A/California/04/09 (H1N1).

3 Jun 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

3 Jun 2011

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of STX209 on social impairment in adolescents and adults with fragile X syndrome.

2 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

Positive interim results from Fraunhofer USA CMB's HAC1 influenza vaccine Phase 1 trial

Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen announced today that Phase 2 data will be presented from an open-label, multi-center clinical trial evaluating the safety and tolerability of rozrolimupab in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP) at the 16th Congress of the European Hematology Association meeting in London, UK on June 10 from 5:45 to 7:00 PM.

2 Jun 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C

Anadys Pharmaceuticals, Inc. today announced issuance of the U.S. patent covering setrobuvir, the Company's Direct-Acting Antiviral in Phase IIb development for chronic hepatitis C virus infection.

2 Jun 2011

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Somnus Therapeutics, Inc., a private specialty pharmaceutical company, has completed a Phase 2 dose-ranging study of SKP-1041, a modified-release formulation of zaleplon.

2 Jun 2011

Fero Industries completes Sucanon human clinical trials on Type-2 diabetes

Fero Industries, Inc. is pleased to announce that independent human clinical trials of Sucanon have been successfully completed in the Middle East.

2 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.

1 Jun 2011

Drug Trial News

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

APC8015F investigational vaccine improves survival of prostate cancer patients

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis

Angiotensin receptor blockers do not increase risk of cancer: FDA

Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Positive interim results from Fraunhofer USA CMB's HAC1 influenza vaccine Phase 1 trial

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Fero Industries completes Sucanon human clinical trials on Type-2 diabetes

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News